SREBF1 and fatty liver disease: The active forms of SREBP‐1c and SREBP‐2 translocate into the nucleus, bind to sterol regulatory elements (SREs) present in the promoters of their own and target genes, and activate the transcription of SREBP‐responsive genes, thereby promoting the lipogenic process in the liver.5 The pathogenesis of hepatic steatosis, dyslipidaemia, and type 2 diabetes is closely related to the dysregulation of SREBPs.6